122 related articles for article (PubMed ID: 4089533)
1. Serum procollagen III peptide in chronic myeloproliferative disorders.
Hasselbalch H; Junker P; Lisse I; Bentsen KD
Scand J Haematol; 1985 Nov; 35(5):550-7. PubMed ID: 4089533
[TBL] [Abstract][Full Text] [Related]
2. Serum markers for type IV collagen and type III procollagen in the myelofibrosis-osteomyelosclerosis syndrome and other chronic myeloproliferative disorders.
Hasselbalch H; Junker P; Lisse I; Bentsen KD; Risteli L; Risteli J
Am J Hematol; 1986 Oct; 23(2):101-11. PubMed ID: 3752065
[TBL] [Abstract][Full Text] [Related]
3. Procollagen type III aminoterminal peptide in serum in idiopathic myelofibrosis and allied conditions: relation to disease activity and effect of chemotherapy.
Hasselbalch H; Junker P; Hørslev-Petersen K; Lisse I; Bentsen KD
Am J Hematol; 1990 Jan; 33(1):18-26. PubMed ID: 2293759
[TBL] [Abstract][Full Text] [Related]
4. Increased serum procollagen III aminoterminal peptide in myelofibrosis.
Hochweiss S; Fruchtman S; Hahn EG; Gilbert H; Donovan PB; Johnson J; Goldberg JD; Berk PD
Am J Hematol; 1983 Dec; 15(4):343-51. PubMed ID: 6650494
[TBL] [Abstract][Full Text] [Related]
5. [Levels of procollagen type III n-terminal peptide (PIIINP) in serum of patients with myeloproliferative syndrome (mps)].
Podolak-Dawidziak M; Wróbel T; Jeleń M
Pol Arch Med Wewn; 1998 Jan; 99(1):24-9. PubMed ID: 9686500
[TBL] [Abstract][Full Text] [Related]
6. Circulating hyaluronan in the myelofibrosis/osteomyelosclerosis syndrome and other myeloproliferative disorders.
Hasselbalch H; Junker P; Lisse I; Lindqvist U; Engström Laurent A
Am J Hematol; 1991 Jan; 36(1):1-8. PubMed ID: 1984676
[TBL] [Abstract][Full Text] [Related]
7. [Development of polycythemia to myelofibrosis. Monitoring by the assay of the procollagen III amino-propeptide].
Arrago JP; Poirier O; Najean Y
Presse Med; 1984 Nov; 13(40):2429-32. PubMed ID: 6239221
[TBL] [Abstract][Full Text] [Related]
8. Type III aminoterminal propeptide of procollagen in some haematological malignancies.
Arrago JP; Poirier O; Chomienne C; D'Agay MF; Najean Y
Scand J Haematol; 1986 Mar; 36(3):288-94. PubMed ID: 3704553
[TBL] [Abstract][Full Text] [Related]
9. Serum laminin P1 in idiopathic myelofibrosis and related diseases.
Hasselbalch H; Junker P
Leuk Res; 1994 Aug; 18(8):623-8. PubMed ID: 8065164
[TBL] [Abstract][Full Text] [Related]
10. Serum type-III-procollagen and laminin concentration after interferon therapy in chronic myeloproliferative disorders.
Sréter L; Kárteszi M; Fehér J; Lutz D
Acta Med Hung; 1988; 45(3-4):323-8. PubMed ID: 3249659
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow stroma in idiopathic myelofibrosis and other haematological diseases. An immunohistochemical study.
Lisse I; Hasselbalch H; Junker P
APMIS; 1991 Feb; 99(2):171-8. PubMed ID: 2001283
[TBL] [Abstract][Full Text] [Related]
12. Density distribution and size of megakaryocytes in inflammatory reactions of the bone marrow (myelitis) and chronic myeloproliferative diseases.
Thiele J; Holgado S; Choritz H; Georgii A
Scand J Haematol; 1983 Oct; 31(4):329-41. PubMed ID: 6578591
[TBL] [Abstract][Full Text] [Related]
13. [Clinical value of determining the amino terminal fragment of procollagen III in myeloproliferative disorders].
Najean Y; Poirier O; Arrago JP
Nouv Rev Fr Hematol (1978); 1987; 29(2):123-7. PubMed ID: 3615194
[TBL] [Abstract][Full Text] [Related]
14. Serum procollagen-III-peptide level correlates with disease activity in myelofibrosis with myeloid metaplasia.
Barosi G; Costa A; Liberato LN; Polino G; Spriano P; Magrini U
Br J Haematol; 1989 May; 72(1):16-20. PubMed ID: 2736239
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow fibrosis and disease activity in multiple myeloma monitored by the aminoterminal propeptide of procollagen III in serum.
Abildgaard N; Bendix-Hansen K; Kristensen JE; Vejlgaard T; Risteli L; Nielsen JL; Heickendorff L
Br J Haematol; 1997 Dec; 99(3):641-8. PubMed ID: 9401078
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of serum pro-collagen III in chronic myeloproliferative disorders.
Najean Y; Legrand M; Poirier O; Senechal A; Arrago JP
Eur J Haematol; 1990 Nov; 45(5):239-43. PubMed ID: 2261948
[TBL] [Abstract][Full Text] [Related]
17. Increased circulating CSF-1 (M-CSF) in myeloproliferative disease: association with myeloid metaplasia and peripheral bone marrow extension.
Gilbert HS; Praloran V; Stanley ER
Blood; 1989 Sep; 74(4):1231-4. PubMed ID: 2669997
[TBL] [Abstract][Full Text] [Related]
18. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
Ghanima W; Junker P; Hasselbalch HC; Boiocchi L; Geyer JT; Feng X; Gudbrandsdottir S; Orazi A; Bussel JB
Br J Haematol; 2011 Oct; 155(2):248-55. PubMed ID: 21902682
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of multiple myeloma and bone marrow fibrosis with aminoterminal propeptide of type III collagen (PIIINP).
Taube T; Franssila K; Risteli L; Risteli J; Elomaa I
Br J Haematol; 1992 Sep; 82(1):32-7. PubMed ID: 1419800
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
